Priothera SAS
Privately held: no public share price
Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)Small molecule | Acute Myeloid Leukemia |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
May 2027 (1)
Est. primary completion 2027-05 · NCT05429632 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.